Reported 2 months ago
A recent study published in JAMA Internal Medicine suggests Eli Lilly's weight loss drug, tirzepatide, may be more effective than Novo Nordisk's semaglutide based on patient weight loss outcomes. While tirzepatide showed an average weight loss of 26.6% over 84 weeks, semaglutide resulted in 14.9% weight loss over 68 weeks. Despite Eli Lilly's promising results, the competition remains tight, especially with upcoming oral weight loss medications from both companies that could shift market dynamics.
Source: YAHOO